• PP 1 in Context: Src Signaling and EDI3 Research

  2026-10-12

  PP 1 is described by APExBIO as a Src-family tyrosine kinase inhibitor, whereas Keller et al. investigated EDI3/GPCPD1 in therapy-resistant ER-HER2-positive breast cancer. The cited study supports EDI3 as a research target, but it does not establish a role for PP 1 or Src-family kinases in that mechanism.

• PAD4-IN-2 TFA: What the Preclinical Evidence Shows

  2026-10-12

  The 2023 study provides hypothesis-generating cell and mouse evidence that a PBA-modified PAD4 inhibitor can reduce histone H3 citrullination, NET-associated tumor biology, and metastasis-related phenotypes. The findings remain preclinical and do not establish human efficacy, clinical safety, or that a commercial PAD4-IN-2 TFA sample was used.

• Moesin as a Biomarker of Endothelial Injury in Sepsis

  2026-10-10

  Chen et al. combine patient biomarker data, mouse models of sepsis, and endothelial-cell experiments to position moesin as a candidate indicator of endothelial injury and disease severity. The study also links moesin silencing with reduced ROCK1/MLC and NF-κB signaling and lower endothelial monolayer permeability, while leaving clinical validation and in vivo causality unresolved.

• Ibrexafungerp Against Fluconazole-Resistant C. auris

  2026-10-09

  Wiederhold and colleagues evaluated ibrexafungerp against fluconazole-resistant Candida auris using in vitro susceptibility testing and a delayed-treatment murine model of invasive candidiasis. The study found consistent ibrexafungerp activity across 54 isolates and improved survival and kidney fungal-burden outcomes in vivo, supporting further investigation of an orally active glucan-synthesis inhibitor for infections involving limited antifungal options.

• 25-Hydroxycholesterol Reprograms Tumor Macrophages

  2026-10-09

  Xiao et al. identify CH25H-derived 25-hydroxycholesterol as an immunometabolic checkpoint that links lysosomal lipid handling to AMPKα–STAT6 signaling in tumor-associated macrophages. The study suggests that disrupting this axis can improve T-cell infiltration and strengthen anti-PD-1 responses in preclinical models, while leaving important questions about clinical translation and cell-type specificity.

• KLF6 Super-Enhancer Control in Human Adipogenesis

  2026-10-08

  Nguyen et al. identify a KLF6-proximal super-enhancer as an important regulatory hub during the adipogenic differentiation of human adipose-derived stem cells. Their evidence connects PPARγ-associated enhancer activity, enhancer RNA, KLF6, HDAC3, and DLK1 into a mechanistic model that helps explain how adipogenic gene programs are established.

• ARCA and Synthetic mRNA: Five Evidence Questions

  2026-10-08

  A source-grounded overview of Anti Reverse Cap Analog, 3´-O-Me-m7G(5')ppp(5')G, covering cap biology, evidence quality, interpretation of an oligodendrocyte study, applicability and key limitations.

• Risedronate Sodium: Evidence and Research Context

  2026-10-07

  Risedronate Sodium is an FPP synthase inhibitor with an established bone-metabolism research context and an emerging, but preliminary, pulmonary repurposing hypothesis. This overview examines the mechanism, findings from a 2021 rat emphysema study, evidence strength, translational boundaries, and the limitations of interpreting inhaled formulations as potential emphysema therapies.

• Ricin Bystander Necroptosis in Lung Epithelium

  2026-10-07

  Kempen and colleagues show that ricin-exposed monocytic cells can transmit a soluble death signal to lung epithelial cells, producing bystander necroptosis rather than simply extending direct toxin injury. The study connects released ricin, Fas ligand, HMGB1, RAGE-associated reactive oxygen species, and inflammatory amplification while defining important boundaries for interpreting apoptosis and cell-death assays.

• Spatially Patterned Kidney Assembloids for Disease Modeling

  2026-10-06

  Huang et al. developed mouse and human kidney progenitor assembloids that reproduce key aspects of nephron–collecting-system assembly, spatial organization, maturation, and function. Their PKD2-deficient human model also captured cystic disease features and multicellular interactions, supporting assembloids as high-fidelity platforms for kidney disease research while leaving important translational questions unresolved.

• Azithromycin: Evidence, Resistance, and Research Context

  2026-10-06

  Azithromycin is a macrolide antibiotic used in bacterial infection research, antimicrobial resistance surveillance, and selected preclinical models. Recent Beijing data show complete in vitro resistance among 62 Mycoplasma pneumoniae isolates, while the available evidence remains geographically limited and should not be extrapolated directly to other organisms, regions, or clinical settings.

• Isradipine (Dynacirc): Reading Calcium Data Precisely

  2026-10-05

  Isradipine (Dynacirc) is an L-type calcium-channel tool whose value depends on careful separation of channel subtype, cellular context, and biological interpretation. This evidence-centered guide connects its vascular and neuronal research applications with a key caution from toxin pharmacology.

• Nilotinib Research Context and Evidence

  2026-10-05

  Nilotinib, also known as AMN-107, is a kinase inhibitor studied in BCR-ABL-driven leukemia and other kinase-dependent cancer models. This overview distinguishes supplier-reported activity from peer-reviewed or academic evidence, explains conceptual research applications, and examines the limitations of common in vitro response metrics.

• Alfuzosin HCl: Research Context and Evidence

  2026-10-04

  This overview places Alfuzosin HCl research in the context of α1-adrenoceptor pharmacology, lower urinary tract smooth muscle studies, and benign prostatic hyperplasia research. It also separates supplier-described properties from peer-reviewed findings and explains why the supplied gepotidacin trials cannot be used as direct evidence for alfuzosin.

• Cyclosporin A: Mechanisms, Findings, and Limits

  2026-10-03

  Cyclosporin A is a membrane-permeable cyclic undecapeptide widely studied in immunosuppression and mitochondrial biology. This overview compares its established research context with findings from a 2020 study of cyclosporin B–E, emphasizing structure–activity relationships, evidence strength, conceptual applications, and limitations.

8435 records 1/563 page Next 12345 下5页 Last page